Werewolf Therapeutics logo — Advancing a pipeline of next generation, transformative immu...

Werewolf Therapeutics

Advancing a pipeline of next generation, transformative immuno-stimulatory medicines for cancer patients.

Founded 2017 United States Watertown, United States 27 employees Post Ipo Secondary Total: $178.17M Biotechnology, Health and Wellness +1

General Information

Company Name Werewolf Therapeutics
Founded Year 2017
Location United States Watertown, United States +1
Employees 27
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Post Ipo Secondary
Social

Get notified when Werewolf Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Werewolf Therapeutics

Werewolf Therapeutics is a biotechnology startup, founded in 2017 and based in the United States. The company is driven by the mission of advancing a pipeline of next-generation, transformative immuno-stimulatory medicines for cancer patients. Their slogan, "Advancing a pipeline of next generation, transformative immuno-stimulatory medicines for cancer patients," underscores their commitment to leveraging innovative solutions in the field of immuno-oncology.

Their recent $50.00M post-IPO secondary investment on 10 May 2022 signifies a significant milestone for the company, demonstrating the confidence of investors in their vision and capabilities. While the details of the specific investors involved in this round are not provided, the substantial investment amount attests to the level of interest Werewolf Therapeutics has garnered in the investment community.

As the company continues to progress in the advancement of their pipeline, this recent investment serves as a testament to their potential impact in the biotechnology sector and their dedication to improving treatment options for cancer patients.

Taxonomy: immuno-oncology, biopharmaceutical, therapeutics, cancer treatments, immune system stimulation, oncology, biopharma innovation, cancer therapeutics, immunotherapy, transformative medicines

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Secondary •••••• - 10 May 2022
Series B •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor
•••• ••••
07 Jan 2021
Series A •••••• - 20 Nov 2019

Werewolf Therapeutics Alternatives & Competitors

Werewolf Therapeutics vs

Biotech Company 100% Focused on Pediatric Cancer Drug Development

Series Unknown
10 employees
Biotechnology
Werewolf Therapeutics vs
Alv B AS
Alv B AS Norway

COMPARATIVE ONCOLOGY & IMMUNOTHERAPY

12 employees
Biotechnology
Werewolf Therapeutics vs

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastat...

Convertible Note
2 employees
Health Care, Health and Wellness

FAQ About Werewolf Therapeutics

Advancing a pipeline of next generation, transformative immuno-stimulatory medicines for cancer patients.
Werewolf Therapeutics was founded in 2017.
Werewolf Therapeutics is headquartered in Watertown, United States.
Werewolf Therapeutics operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.
Werewolf Therapeutics has approximately 27 employees.
Werewolf Therapeutics has completed 3 funding rounds, raising a total of $178.17M. The latest funding stage is Post Ipo Secondary.
Top alternatives and competitors to Werewolf Therapeutics include Oncoheroes Biosciences, Alv B AS, Probmet Therapeutics, ApoGen Biotechnologies, Inc., PanTher Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Werewolf Therapeutics and Oncoheroes Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Werewolf Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy